Gamma Medica-Ideas Announces the Sale of a Fully Digital Multi-Modality Pre-Clinical Imaging System to Louisiana State University Health Sciences Center
Los Angeles, CA, December 07, 2007 --(PR.com)-- Gamma Medica-Ideas Inc. (GM-I), the world leader in developing and delivering digital medical imaging devices for the pre-clinical and clinical markets, has announced the sale of a fully digital multi-modality molecular imaging system for installation at Louisiana State University Health Sciences Center in Shreveport, LA (LSUHSC-S). The Small Animal Imaging Core at LSUHSC-S order for the FLEX Triumph™ pre-clinical platform system includes an X-SPECT® MicroSPECT® system with digital CZT detectors as well as an X-O® Micro-CT system. The sale also represents the first digital LabPET™ system to be incorporated into the FLEX Triumph platform.
"The FLEX Triumph system will dramatically increase the imaging capabilities of our Small Animal Imaging Core by providing SPECT imaging as well as the ability for multimodality imaging" said Dr. Michael Mathis, Imaging Core Director at LSUHSC-S. "Particularly important for researchers at LSUHSC-S will be the development of combination PET and SPECT imaging to provide imaging of molecular targets and therapeutic responses."
The Small Animal Imaging Core at LSUHSC-S was founded in 2004 with joint funding from the Louisiana Gene Therapy Research Consortium, the LSUHSC-S Institute for Cardiovascular Disease and Imaging, the LSUHSC-S Neurobiotechnology Program, the Biomedical research Foundation of NW Louisiana, and the Feist-Weiller Cancer Center. The Small Animal Imaging Core is operated as a component of the LSUHSC-S Research Core Facility with capabilities to perform pre-clinical PET imaging, Micro-CT imaging, and bioluminescence/fluorescence imaging. The Core supports molecular imaging applications for cancer, including early detection of cancer and therapy evaluation. In addition, imaging applications for cardiovascular and neurodegenerative diseases are supported.
In 2007, additional funds to expand the Small Animal Imaging Core were obtained through the Louisiana Gene Therapy Research Consortium and the LSUHSC-S Institute for Cardiovascular Disease and Imaging. These funds were used to purchase a FLEX Triumph multi-modality system from Gamma-Medica Ideas. In support of pre-clinical PET imaging at LSUHSC-Shreveport, the Biomedical Research Foundation is among the few PET Centers in the world with its own cyclotron.
Gamma Medica-Ideas’ FLEX Triumph multi-modality pre-clinical platform offers multiple configurations to meet user needs. It can combine up to three different imaging modalities (PET, SPECT, and CT) in a single platform. Key application areas include cardiology, neurology, oncology, and bone analysis. The platform is designed and manufactured to be easily upgradeable to fit growing needs.
About Gamma Medica-Ideas, Inc.
Gamma Medica-Ideas (GM-I) designs, builds and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment and by enabling new drug discovery. GM-I is dedicated to leading medical imaging into a new digital era with its unique sensor readout systems. The company’s core digital imaging technologies also hold great promise for a new class of solutions for the safety and security markets. In the pre-clinical space, GM-I’s FLEX Triumph™ imaging platform is marketed for medical research and drug development. The FLEX Triumph system combines PET (X-PET™ or its new fully digital LabPET™), SPECT (X-SPECT®) and CT (X-O™) modalities in the world’s first tri-modality system. In the clinical space, GM-I offers LumaGEM®, its dual-headed Molecular Breast Imaging (MBI) based system for early diagnosis and treatment of breast cancer. The digital gamma ray imaging technology in LumaGEM offers significant advances in resolution and contrast which has allowed for identification of millimeter sized breast cancers missed by mammography, especially in women with dense breast tissue.
###
"The FLEX Triumph system will dramatically increase the imaging capabilities of our Small Animal Imaging Core by providing SPECT imaging as well as the ability for multimodality imaging" said Dr. Michael Mathis, Imaging Core Director at LSUHSC-S. "Particularly important for researchers at LSUHSC-S will be the development of combination PET and SPECT imaging to provide imaging of molecular targets and therapeutic responses."
The Small Animal Imaging Core at LSUHSC-S was founded in 2004 with joint funding from the Louisiana Gene Therapy Research Consortium, the LSUHSC-S Institute for Cardiovascular Disease and Imaging, the LSUHSC-S Neurobiotechnology Program, the Biomedical research Foundation of NW Louisiana, and the Feist-Weiller Cancer Center. The Small Animal Imaging Core is operated as a component of the LSUHSC-S Research Core Facility with capabilities to perform pre-clinical PET imaging, Micro-CT imaging, and bioluminescence/fluorescence imaging. The Core supports molecular imaging applications for cancer, including early detection of cancer and therapy evaluation. In addition, imaging applications for cardiovascular and neurodegenerative diseases are supported.
In 2007, additional funds to expand the Small Animal Imaging Core were obtained through the Louisiana Gene Therapy Research Consortium and the LSUHSC-S Institute for Cardiovascular Disease and Imaging. These funds were used to purchase a FLEX Triumph multi-modality system from Gamma-Medica Ideas. In support of pre-clinical PET imaging at LSUHSC-Shreveport, the Biomedical Research Foundation is among the few PET Centers in the world with its own cyclotron.
Gamma Medica-Ideas’ FLEX Triumph multi-modality pre-clinical platform offers multiple configurations to meet user needs. It can combine up to three different imaging modalities (PET, SPECT, and CT) in a single platform. Key application areas include cardiology, neurology, oncology, and bone analysis. The platform is designed and manufactured to be easily upgradeable to fit growing needs.
About Gamma Medica-Ideas, Inc.
Gamma Medica-Ideas (GM-I) designs, builds and services imaging systems based on novel technologies to improve patient health through early diagnosis of disease, improved patient treatment and by enabling new drug discovery. GM-I is dedicated to leading medical imaging into a new digital era with its unique sensor readout systems. The company’s core digital imaging technologies also hold great promise for a new class of solutions for the safety and security markets. In the pre-clinical space, GM-I’s FLEX Triumph™ imaging platform is marketed for medical research and drug development. The FLEX Triumph system combines PET (X-PET™ or its new fully digital LabPET™), SPECT (X-SPECT®) and CT (X-O™) modalities in the world’s first tri-modality system. In the clinical space, GM-I offers LumaGEM®, its dual-headed Molecular Breast Imaging (MBI) based system for early diagnosis and treatment of breast cancer. The digital gamma ray imaging technology in LumaGEM offers significant advances in resolution and contrast which has allowed for identification of millimeter sized breast cancers missed by mammography, especially in women with dense breast tissue.
###
Contact
Gamma Medica-Ideas
Marie-France Lamoureux
819-212-4422
www.gm-ideas.com
Marie-France Lamoureux
819-212-4422
www.gm-ideas.com
Contact
Categories